RVL Pharmaceuticals plc

OTCPK:RVLP.Q Stock Report

Market Cap: US$111.0

RVL Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

RVL Pharmaceuticals's earnings have been declining at an average annual rate of -3.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 5.6% per year.

Key information

-3.4%

Earnings growth rate

17.7%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate5.6%
Return on equity-418.1%
Net Margin-184.9%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 16
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

May 13
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

May 12
RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Apr 20
RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

Jan 05
Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M

Oct 18

RVL Pharmaceuticals: Chapter 2 - A Developing Quandary

Sep 22

RVL Pharma in pact with Revision Skincare to broaden access to products

Aug 30

GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M

Aug 11

RVL Pharma posts preliminary 42% sales growth for eye treatment

Jul 07

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Jul 04
RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture

Jun 15

New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

Apr 01
New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

RVL Pharmaceuticals: A Makeover For An Ugly Duckling

Mar 30

Osmotica: A Different Breed Of Cat

Dec 14

Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Aug 20
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Osmotica: Paring Down, Focusing On UPNEEQ

Jul 16

Revenue & Expenses Breakdown

How RVL Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:RVLP.Q Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2337-68673
31 Mar 2337-56714
31 Dec 2250-52794
30 Sep 2243-53854
30 Jun 2235-66935
31 Mar 2238-76914
31 Dec 2118-83846
30 Sep 2116-115819
30 Jun 2140-86749
31 Mar 2128-827211
31 Dec 2028-897313
30 Sep 2087-647518
30 Jun 20126-1787824
31 Mar 20183-2859027
31 Dec 19240-2719332
30 Sep 19246-3519538
30 Jun 19247-2438840
31 Mar 19261-1127943
31 Dec 18264-1107443
30 Sep 18274-16753
30 Jun 18262-106350
31 Mar 18248-316047
31 Dec 17246-415742
31 Dec 16218-426329

Quality Earnings: RVLP.Q is currently unprofitable.

Growing Profit Margin: RVLP.Q is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if RVLP.Q's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare RVLP.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RVLP.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: RVLP.Q has a negative Return on Equity (-418.14%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies